A research article published in the journal Science has reported the efficacy of three
different vaccine platforms against the Zika virus in rhesus macaque monkeys.
Not exact matches
The Fraunhofer IME leads the Transnational Access 1 (TNA1) «Cross
platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «both aiming at the provision of comprehensive range of
different well established pro- and eukaryotic expression / production systems to identify the optimal manufacturing
platform for any given
vaccine candidate.
The Transnational Access 1 (TNA1) «Cross
platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «will combine the expertise of six
different partners (IME, SSI, UOXF, iBET, BPRC and UNISI) to provide the unique offer to test
vaccine candidates in a comprehensive range of
different expression hosts, to identify the optimal production system for further pre-clinical and clinical development.
The integrated production
platform aims to produce and purify these proteins using a combination of engineered microbial cell factories and flexible approaches for purification to accommodate
different vaccines and future candidates.
Research on
vaccine biomarkers, including in - depth comparative analysis of data from
different platforms, large - scale RNA sequencing, harmonisation of standard operating procedures (SOPs) for sample, microarray and data analysis, as well as transcriptome mapping (more than 1400 samples analysed).
The IME Molecular Biology Division has a long standing expertise in the expression of recombinant proteins like therapeutic antibodies and
vaccines using
different expression
platforms.
The service «Expression of
vaccine antigens in plant - based systems» can be requested as a standalone service, or in the context of the «Cross-platform screening and optimization service» which enabled the user to have
vaccine antigens expressed in several
different platforms with the aim to compare yields, integrity and (if possible) functionality of the protein when produced in
different systems.
The Agrobacterium tumefaciens - based system is a robust
platform to either rapidly produce up to mg - amounts of recombinant proteins or to compare larger numbers of
different vaccine constructs in a screening approach preferentially by transient expression in N. benthamiana plants.